Researchers in Japan he initiated clinical trials for a novel drug designed to stimulate tooth regrowth in individuals with congenital tooth agenesis, potentially revolutionizing dental care.
The drug, an antibody targeting USAG-1 protein, has shown promise in preclinical studies by inducing new tooth growth in mice and ferrets with missing teeth.
The Phase 1 trial will assess the drug's safety and efficacy in children aged 2-6 with anodontia, a condition characterized by the absence of some or all teeth.